Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.
| Autor: | Kálovits F; Department of Neurosurgery, Markusovszky University Teaching Hospital, Szombathely.; Graduate Studies in Clinical Neurosciences, University of Pécs, Pécs., Tompa M; Graduate Studies in Clinical Neurosciences, University of Pécs, Pécs., Nagy Á; Molecular Pathology, Markusovszky University Teaching Hospital, Szombathely., Kálmán B; Graduate Studies in Clinical Neurosciences, University of Pécs, Pécs.; Molecular Pathology, Markusovszky University Teaching Hospital, Szombathely. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Ideggyogyaszati szemle [Ideggyogy Sz] 2018 Jul 30; Vol. 71 (7-08), pp. 237-247. |
| DOI: | 10.18071/isz.71.0237 |
| Abstrakt: | Background and Purpose: Oncogenesis is related to a sequential accumulation of somatic mutations. Comprehensive characterizations of the genomic landscapes have been completed recently for several tumors, glioblastoma being among the first ones. Our own translational research studies have been focused on defining molecular subtypes of glioblastoma in the clinical setting because of an expected prognostic and therapeutic utility of the information. Somatic mutations in genes of the isocitrate dehydrogenase (IDH) enzyme family appear to be among the best-defined biomarkers that also influence tumor behavior and confer clinical utility. Methods: We have reviewed the literature including our own results to summarize basic science and clinical correlates of IDH mutations. Results: The surveyed data reveal genomic, transcriptomic, epigenomic and biochemical consequences of IDH mutations in the context of glioblastoma biology and phenotype. In addition, a few studies highlight the therapeutic potential of targeting IDH, although thus far all tests have only been conducted in the preclinical setting. Conclusion: Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|